Abstract
Purpose
To examine the incidence and characteristics of metachronous contralateral breast cancer (CBC) among women in the Canton of Zurich, Switzerland.
Methods
For 1980–2006, patients with unilateral invasive breast cancer (UBC) were analysed for metachronous CBC. Poisson’s regression was used to estimate incidence rates of metachronous CBC according to age, year of diagnosis, follow-up period since first breast cancer and morphology.
Results
Of 16,323 patients with UBC, 700 (4.3 %) developed a second malignant tumour of the opposite breast. Median age at first breast cancer was lower in the CBC group than in the full cohort. Median interval time between first and second breast cancer was 5.5 (interquartile range 2.6–10.1) years. Incidence rate at age 20–29 was 1006 (95 % confidence interval, CI, 452–2238) cases per 100,000 person-years and decreased to 299 (199–450) at 80–84. Age-adjusted incidence rates according to period of diagnosis decreased from 618 (530–721) for 1980–1984 to 329 (217–500) cases per 100,000 person-years for 2005–2006. Incidence rate ratio of CBC for lobular carcinoma was 1.28 (95 % CI 0.99–1.67) adjusted by age group and period of diagnosis compared to ductal carcinoma.
Conclusions
In our study, incidence rates for CBC are comparable with findings from the literature. A reduction in the incidence of metachronous CBC, thought to be due to adjuvant therapies, is seen in our data. In our cohort, younger age and lobular carcinoma were associated with an increased risk of CBC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alkner S, Bendahl PO, Ferno M, Manjer J, Ryden L (2011) Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer 11:114. doi:10.1186/1471-2407-11-114
Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:R149–R156. doi:10.1186/bcr767
Bernstein JL, Lapinski RH, Thakore SS, Doucette JT, Thompson WD (2003) The descriptive epidemiology of second primary breast cancer. Epidemiology 14:552–558. doi:10.1097/01.ede.0000072105.39021.6d
Bertelsen L et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women’s environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 100:32–40. doi:10.1093/jnci/djm267
BFS Statistical office (2010) Bilanz der ständigen Wohnbevölkerung, Kanton Zürich, 1971–2010. STAT-TAB Federal Statistical Office Switzerland, Neuchatel
Bodmer A et al (2015) Breast cancer in younger women in Switzerland 1996–2009: a longitudinal population-based study. Breast 24:112–117. doi:10.1016/j.breast.2014.11.004
Bouchardy C et al (2011a) Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 127:233–241. doi:10.1007/s10549-010-1137-z
Bouchardy C, Lutz J-M, Kühni C (2011b) Cancer in Switzerland: situation and development from 1983 to 2007. Office fédéral de la statistique (OFS), Neuchâtel
Burstein HJ et al (2014) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269. doi:10.1200/jco.2013.54.2258
Ceschi M, Bopp M, Dick A, Probst-Hensch N (2009) Krebs im Kanton Zürich, Ein Bericht des Krebsregisters vol Nr. 15. Institut für Sozial- und Präventivmedizin der Universität Zürich im Auftrag der Gesundheitsdirektion des Kantons Zürich, Zürich
Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8:855–861
Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma-in situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23:5534–5541. doi:10.1200/jco.2005.04.038
Curtis R et al (2006) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, Bethesda
Cuzick J, Baum M (1985) Tamoxifen and contralateral breast cancer Lancet 2:282
Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lutolf U, Thurlimann B (2010) Geographic variation in breast cancer care in Switzerland. Cancer Epidemiol 34:116–121. doi:10.1016/j.canep.2010.01.008
Font-Gonzalez A et al (2013) Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands. Breast Cancer Res Treat 139:811–819. doi:10.1007/s10549-013-2588-9
Hartman M et al (2007) Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25:4210–4216. doi:10.1200/jco.2006.10.5056
Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2:205–213. doi:10.1038/nrd1031
Kollias J, Ellis IO, Elston CW, Blamey RW (1999) Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 25:584–589. doi:10.1053/ejso.1999.0711
Krebsregister der Kantone Zürich und Zug (2014) Jahresbericht 2013. University Hospital Zurich and University of Zurich, Zürich
Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065. doi:10.1093/jnci/djp181
Levi F, Randimbison L, Te VC, La Vecchia C (2001) Contralateral breast cancer in Vaud, Switzerland. Int J Cancer 93:612–613
Lizarraga IM, Sugg SL, Weigel RJ, Scott-Conner CE (2013) Review of risk factors for the development of contralateral breast cancer. Am J Surg 206:704–708. doi:10.1016/j.amjsurg.2013.08.002
Londero AP et al (2014) Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature. Biomed Res Int 2014:250727. doi:10.1155/2014/250727
Lorez M, Clough-Gorr K, NICER Working Group Cancer Prevalence Trends in Switzerland: 2000–2020. In: Swiss Public Health Conference, Zurich, 2013
Narod SA (2014) Bilateral breast cancers. Nat Rev Clin Oncol 11:157–166. doi:10.1038/nrclinonc.2014.3
Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, Rosenberg PS, Anderson WF (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564–1569. doi:10.1200/JCO.2010.32.7395
Pagani O et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107–118. doi:10.1056/NEJMoa1404037
Rasmussen CB et al (2014) Incidence of metachronous contralateral breast cancer in Denmark 1978–2009. Int J Epidemiol 43:1855–1864. doi:10.1093/ije/dyu202
Rubino C, Arriagada R, Delaloge S, Le MG (2010) Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer 102:213–219. doi:10.1038/sj.bjc.6605434
Rutqvist LE et al (1991) Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83:1299–1306. doi:10.1093/jnci/83.18.1299
Sandberg ME, Hall P, Hartman M, Johansson AL, Eloranta S, Ploner A, Czene K (2012a) Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study. PLoS One 7:e46535. doi:10.1371/journal.pone.0046535
Sandberg ME, Hartman M, Klevebring D, Eloranta S, Ploner A, Hall P, Czene K (2012b) Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer. Breast Cancer Res Treat 134:793–800. doi:10.1007/s10549-012-2096-3
Sawyer E et al (2014) Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet 10:e1004285. doi:10.1371/journal.pgen.1004285
Schaapveld M et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197. doi:10.1007/s10549-007-9709-2
Schmid SM, Pfefferkorn C, Myrick ME, Viehl CT, Obermann E, Schotzau A, Guth U (2011) Prognosis of early-stage synchronous bilateral invasive breast cancer. Eur J Surg Oncol 37:623–628. doi:10.1016/j.ejso.2011.05.006
Soran A, Kamali Polat A, Johnson R, McGuire KP (2014) Increasing trend of contralateral prophylactic mastectomy: What are the factors behind this phenomenon? Surgeon. doi:10.1016/j.surge.2014.02.005
Verkooijen HM et al (2007) Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105:347–357. doi:10.1007/s10549-006-9455-x
Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Luchtenborg M (2011a) Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Res Treat 130:609–618. doi:10.1007/s10549-011-1618-8
Vichapat V, Gillett C, Fentiman IS, Tutt A, Holmberg L, Luchtenborg M (2011b) Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. Eur J Cancer 47:1919–1927. doi:10.1016/j.ejca.2011.05.004
Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Luchtenborg M (2012) Patterns of metastasis in women with metachronous contralateral breast cancer. Br J Cancer 107:221–223. doi:10.1038/bjc.2012.273
Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA (2009) Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat 117:365–370. doi:10.1007/s10549-008-0265-1
Acknowledgments
Julia Prater was funded by Cancer League Zurich.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human patients and/or animals and informed consent
Cancer cases in the Canton of Zurich are registered with presumed consent and registration based on a decision by the Zurich Government Council from 1980 and the general registry approval by the Federal Commission of Experts for professional secrecy in medical research from 1995. All data were used anonymously in this analysis, and no approval from the Ethical Committee of the Canton of Zurich was necessary.
Rights and permissions
About this article
Cite this article
Prater, J., Valeri, F., Korol, D. et al. Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry. J Cancer Res Clin Oncol 142, 365–371 (2016). https://doi.org/10.1007/s00432-015-2031-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-015-2031-1